Mucinous Breast Carcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive adenocarcinoma of the breast characterized by the presence of islands of small and uniform cells, surrounded by large amounts of mucin. Pure mucinous breast carcinomas generally have a favorable prognosis. 
Mucinous breast carcinomas most frequently harbor alterations in GATA3, CCND1, FGF19, BRIP1, and FGF4 .
GATA3fs, CCND1 Amplification, FGF19 Amplification, BRIP1 Amplification, and FGF4 Amplification are the most common alterations in mucinous breast carcinoma .
There is 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains mucinous breast carcinoma as an inclusion criterion, 1 is phase 1 (1 open).
ER, HER2, and PR are the most frequent gene inclusion criteria for mucinous breast carcinoma clinical trials .
Radiation therapy is the most common intervention in mucinous breast carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.